From afa5322aa396f3a1fed8cf494fad7af7491bba77 Mon Sep 17 00:00:00 2001 From: Borja Robert Date: Thu, 21 Mar 2024 15:46:00 +0100 Subject: [PATCH] Auto saved by Logseq --- pages/STOP2030___Web___Posts.md | 2 +- 1 file changed, 1 insertion(+), 1 deletion(-) diff --git a/pages/STOP2030___Web___Posts.md b/pages/STOP2030___Web___Posts.md index e1efb60f..5b1f4052 100644 --- a/pages/STOP2030___Web___Posts.md +++ b/pages/STOP2030___Web___Posts.md @@ -5,7 +5,7 @@ - #+BEGIN_VERSE At STOP2030 we want to provide a pharmacological tool that helps at delivering WHO's elimination goals for soil-transmitted helminthiasis (STH). We are happy to announce that we've completed the design of the REALISE study (Real world Evaluation of an ALbendazol-Ivermectin coformulation Safety and Effectiveness), our largest clinical trial. - The details of the REALISE study have been published in ClinicalTrials.gov and the Pan African Clinical Trial Registry. These details will soon be shared with the Institutional Review Boards (IRBs) in Ghana and Kenya, the two countries where patient recruitment and treatment administration will take place. + The details of the REALISE study have been published in ClinicalTrials.gov and the Pan African Clinical Trial Registry. These details will soon be shared with the Institutional Review Boards (IRBs) in Ghana and Kenya, the two countries where patient recruitment and treatment administration will take place. The publication is an important milestone The design of this clinical trial was lead by the teams at ISGlobal and Liconsa, with support from GHS (Ghana Health Service) and KEMRI (Kenya Medical Research Institute) and other partners in our Consortium.